Dr. John Cush RheumNow
1 year 1 month ago
LIVE Daily Recap – EULAR 2025 Coverage
Date: Thursday, 06/12, Friday, 06/13 and Saturday, 06/14
Time: 12 (noon) ET
🔗 Tune in and join the conversation: YouTube, X, Facebook Live & LinkedIn
#RheumNow#EULAR25 #Rheumatology #MedTwitter #HCPs #RheumatologyEducation https://t.co/1qlcKDOL64
Jiha Lee JihaRheum
1 year 1 month ago
📊 In a 40-yr cohort (n=2818), RA pts had 2.3x ↑ risk of DVT (HR 2.26) & 1.6x ↑ risk of PE (HR 1.61) vs non-RA.
Risk ↑ with RF/CCP+, nodules (HR 2.9), BMI ≥30 (HR 1.9), & biologic use in year 1 (HR 2.4–2.9).
Remission = ↓ PE risk (HR 0.47)
📍OP0070
@RheumNow #EULAR2025
Jiha Lee JihaRheum
1 year 1 month ago
POS0627: RA patients aged ≥90 yrs can benefit from biologics/JAKi! In 3,600 pts, 84% of those ≥90 achieved low disease activity, 71% were on JAKi. But serious infections occurred in 21%—mostly pneumonia. Use w/caution in the oldest-old. #EULAR2025 @rheumnow
Janet Pope Janetbirdope
1 year 1 month ago
#Probiotics +#methotrexate giving far more #remission in #rheumatoid #arthritis than #MTX alone?
Seems fishy….
oops - #fish #oil #omega3 #fatty #acids do work!
not sure re the huge benefit of ‘immunebiotics’
#EULAR2025 @RheumNow @eular_org abst#POS0483 https://t.co/STQuaOkBcY
Bella Mehta bella_mehta
1 year 1 month ago
Closing the care divide in #JIA treatment plenary session
Overall theme in #EULAR2025 is everyone talking about AI and digital health on day 1
Biologics have changed the game!
@RheumNow https://t.co/qDqbz8JApe
Adela Castro AdelaCastro222
1 year 1 month ago
Data from a German cohort evaluated the frequency of D2M-axSpA using the new D2M definition and showed:
> Female pts
> Peripheral SpA symptoms
< HLAB27 positive
< Education level
< Objective signs: MRI-inflammation in the spine or elevated CRP levels.
also PROs were worse in
This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases. Across multiple sessions and studies, delegates are presenting compelling evidence and ground-breaking research demonstrating that who you are, where you live, and what resources you can access truly do shape the trajectory of chronic illness just as much as biological factors.
The concept of Difficult-to-Manage (D2M) axial spondyloarthritis (axSpA) is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. This unified definition has stimulated a wave of new research globally, with multiple studies analysing D2M axSpA in diverse clinical cohorts.
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 1 month ago
#EULAR2025 Abstr#OP0077 Which MSK item/tool is important when assessing #SLE arthritis?Cohort study showed:
-SJC = good specificity. Correlated with US synovitis but not patient-defined response
-New tool, LAMDA correlated with US & patient response. May be used in RCT @RheumNow https://t.co/srVLKw2pcL
Nelly ZIADE 🍀 Nellziade
1 year 1 month ago
❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis?
🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro
#EULAR2025
OP0090
@RheumNow
#Strategy https://t.co/W8fuzSgxbJ
Aurelie Najm AurelieRheumo
1 year 1 month ago
Ph 2 RCT Sonelokimab (IL-17A- & IL-17F-inhibiting Nanobody) 24wks
207 pts SON 120 MDA 51% vs. 45% ADA
Subgroups: female 52%, weight ≥100kg 53%, ≥3% BSA 55%
Composite ACR70/PASI100 SON 120 48% vs. 19% ADA
No new safety signal
Ph 3 on the way 2 doses SON 60 &120
#OP0096 https://t.co/w5QtpKbi1W
Mrinalini Dey DrMiniDey
1 year 1 month ago
Young Patients’ AREA empowers teens/young adults w/ autoimmune disease to shape research. US-based, youth-led & grounded in empowerment, they co-design studies, train peers & advise researchers. A truly positive and meaningful initiative esp for PPIE
@RheumNow #EULAR2025 #OP0008
Antoni Chan MD (Prof) synovialjoints
1 year 1 month ago
Efficacy and safety of deucravacitinib up to week 52 in the POETYK PsA-2 study
•ACR20 at W16: 54.2% (deucravacitinib) vs 39.4% (placebo), p=0.0002
•PASI75: 40.9% vs 15.4%, p<0.0001
•MDA: 25.6% vs 14.7%, p=0.0007
•FACIT-F: +2.5 vs +1.8
•SAE: 1.9% (low)
TYK2 inhibition shows https://t.co/JXTZRk2itA
Nelly ZIADE 🍀 Nellziade
1 year 1 month ago
❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis?
🅰️ Yes
🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025
OP0089
@RheumNow
#Strategy https://t.co/24e7wUV2FB

